Citius Pharmaceuticals, Inc. CTXR
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Citius Pharmaceuticals, Inc. (CTXR) is a healthcare company listed in the US with a market value of about $15M.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -25%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
About Citius Pharmaceuticals
Citius Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $50000 in 2017 to $90000 in 2022, growth of about 12.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 89% over three years (dilution for shareholders).
Score: 0.2 / 5
Checks passed
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $90000 | $90000 | $90000 | $90000 | $75000 | $50000 | — |
| Net income | -$37M | -$40M | -$33M | -$34M | -$23M | -$18M | -$16M | -$13M | -$10M | -$8M |
| Free cash flow | — | — | — | — | -$24M | -$17M | — | — | -$8M | — |
| EPS (diluted) | $-3.38 | $-5.97 | $-5.57 | $-5.75 | $-5.75 | $-11.25 | $-19.25 | $-29.25 | $-47.25 | $-57.25 |
| Net margin | — | — | — | -37378.5% | -25616.0% | -19497.9% | -17291.3% | -16715.5% | -20769.9% | — |
| ROIC | -8.3% | -47.2% | -31.8% | -25.4% | -14.0% | -40.0% | -43.3% | -35.4% | -35.7% | -33.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Citius Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Citius Pharmaceuticals pay a dividend?
Not currently.
Is Citius Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Citius Pharmaceuticals scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.